Hyperion Therapeutics (FRA:0HY) Net Change in Cash : €5.2 Mil (TTM As of Mar. 2015)

View and export this data going back to . Start your Free Trial

What is Hyperion Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Hyperion Therapeutics's Net Change in Cash for the three months ended in Mar. 2015 was €-12.8 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2015 was €5.2 Mil.

Hyperion Therapeutics Net Change in Cash Historical Data

The historical data trend for Hyperion Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperion Therapeutics Net Change in Cash Chart

Hyperion Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Net Change in Cash

-2.64

0.33

32.64

17.80

23.17

Hyperion Therapeutics Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Net Change in Cash	Get a 7-Day Free Trial													4.01	0.63	11.69	5.76	-12.85

Hyperion Therapeutics Net Change in Cash Calculation

Hyperion Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2014 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	25.139	+	-12.143	+	10.169	+	0
	=	23.2

Hyperion Therapeutics's Net Change in Cash for the quarter that ended in Mar. 2015

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 5.175 + -19.609 + 1.588 + 0

= -12.8

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyperion Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Hyperion Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyperion Therapeutics (FRA:0HY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyperion Therapeutics Inc (FRA:0HY) » Definitions » Net Change in Cash

Comparable Companies

XKRX:005250 FIXX HKSE:01672 VCYT RARX OSTO:RECI B OSTO:HNSA OMER XPAR:GNFT TSX:PLI CBAY NSTG TSE:4565 RCKT CLVS EIDX WVE VNDA DCPH DRNA

Traded in Other Exchanges

N/A

Address

Website

http://www.hyperiontx.com

Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Hyperion Therapeutics (FRA:0HY) Headlines

No Headlines